The rare disease space is often overlooked, but it may be the most important laboratory we have for the future of medicine. Jimmy sits down with Rob Freishtat, board member of the Foundation for mRNA Medicines, to talk about what is actually driving collaboration between academic institutions and industry, what a changing regulatory landscape means for sites, and why financial viability and patient access are not as opposed as people think. Tune in now.

What happens when a research site gets so frustrated with disconnected systems that they decide to build their own? In this episode, Jimmy Bechtel sits down with Brian Hunter, COO, and Florin Petrutiu, CIO of Site Centric, to hear exactly that story. Born out of CNS Healthcare over 18 years ago, Site Centric has evolved from an internal workaround into a full CTMS platform now available to sites everywhere. Brian and Florin share how their hands-on site experience shaped every corner of the platform, how they're integrating AI tools without adding operational burden, and why becoming an SCRS Global Impact Partner felt like a natural next step.

What does it actually mean to be a sponsor of choice? In this episode, Jimmy Bechtel sits down with Carrie Lewis and Suzy Montanye from Keenova to find out. The two share how the newly formed company, born from the merger of Mallinckrodt and Endo, is building a site partnership model grounded in accountability, transparency, and real feedback. From their site operational advisory board to a dedicated site relationship manager role, Keenova is making the case that mid-sized sponsors can operate like industry leaders.